CN101951880A - Composition for skin whitening containing diosgenin - Google Patents
Composition for skin whitening containing diosgenin Download PDFInfo
- Publication number
- CN101951880A CN101951880A CN2008801260865A CN200880126086A CN101951880A CN 101951880 A CN101951880 A CN 101951880A CN 2008801260865 A CN2008801260865 A CN 2008801260865A CN 200880126086 A CN200880126086 A CN 200880126086A CN 101951880 A CN101951880 A CN 101951880A
- Authority
- CN
- China
- Prior art keywords
- diosgenin
- skin
- composition
- skin whitening
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to a skin-whitening composition, characterized by comprising diosgenin as an active ingredient. The composition comprising diosgenin can be safely used without side effects, and suppress melanin synthesis to inhibit pigmentation, thereby being used for improving melasma or freckles, and whitening skin.
Description
Technical field
The present invention relates to the compositions of skin whitening, and relate more specifically to comprise the compositions that is used for skin whitening of diosgenin, it has good stability and skin is free from side effects, and has by suppressing melanin and generate the excellent results that suppresses the chromogenesis on the skin.
Background technology
The application on human skin color to be by the melanic concentration in the skin and the decision that distributes, and is subjected to ultraviolet, fatigue or pressure in environment or physiologic factor such as the sunlight and the influence of inherited genetic factors.Synthetic melanin is the polyphenol polymer that the form with melanin and protein complex exists in the epidermal melanophore.It is responsible for protecting skin not to be subjected to ultraviolet radiation.The tryrosinase that exists in the known melanocyte is contributor maximum in the melanin biosynthesis.Tryrosinase is the enzyme of the key of skin pigment formation, and catalytic tyrosine is to the conversion of DOPA (DOPA) and DOPA quinone (dopaquinone), and DOPA and DOPA quinone are the intermediate products (intermediate product) that forms during the melanin biosynthesis.Yet the synthetic mechanism of melanin of inducing before tryrosinase works is not still at length illustrated, and is disclosed though produce melanic process by it.
Melanin produces too much can induce variable color, melasma, freckle etc.Therefore, suppress the melanin generation and too much can improve melasma and the freckle of cutaneous pigmentation, and skin brightens and whitening effect as producing owing to UV, hormone and inherited genetic factors.
Generally speaking, conventional material such as hydroquinone, ascorbic acid, kojic acid and the glutathion with tyrosinase inhibitory activity has been used to improve skin whitening effect or pigmentation.Yet hydroquinone has problem, because serious skin irritation has only the amount of strict restriction to be used, even it shows the skin whitening effect.Ascorbic acid is oxidized easily, make cosmetics blended with it have the problem of color and abnormal smells from the patient change, and kojic acid is unstable in solution, and its requires complicated preparation technology.In addition, thiol chemical compound such as glutathion and cysteine have the unique objectionable odor and the problem of Transdermal absorption, and glucosides and derivant thereof have problem, and this is can not use as the blending constituent of cosmetics suitably because they have high polarity.Vitamin C is disadvantageous, because its oxidation easily in aqueous solution, so that can not show its effect constantly.In recent years, developed the skin whitening composition of the extract that comprises natural herbal.Yet,, restricted when mixing because their major parts are colored.In addition, because their effective ingredient is not determined, can not be desirably in and has stable effect in the product.
On the other hand, diosgenin is the sapogenin of plant origin, and it is in the news and reduces arterial pressure and cholesterol steatosis (cholesterin steatosis) is shown prevention and therapeutic effect.At United States Patent (USP) 6,878, in 367, disclose diosgenin and can be used in the Weight reducing compound, because it has the ability of the storage that suppresses fatty tissue mesophytization lipid.In WO97/25049, the compositions that openly comprises diosgenin is used for prevention or treatment osteoporosis.As above mention, carried out many researchs for the effect of natural materials diosgenin.
Disclosure of the Invention
Technical problem
In order to deal with problems, the inventor makes great efforts to have developed a kind of one matter, and it has good whitening effect and stability, and skin is free from side effects, and finishes the present invention thus.
Technical scheme
The purpose of this invention is to provide the skin whitening composition that comprises diosgenin.
Another object of the present invention provides the cosmetic composition that is used for skin whitening that comprises described compositions.
More another purpose of the present invention provides the pharmaceutical composition that is used for skin whitening that comprises described compositions.
The best mode that carries out an invention
According on the one hand, the present invention relates to comprise the skin whitening composition of diosgenin.
Diosgenin of the present invention ((3 β, 25R)-spiral shell steroid-5-alkene-3-alcohol) be the sapogenin of plant origin,, by following formula 1 representative.
[chemical graph 1]
Diosgenin of the present invention can be from natural source (for example, Japan Rhizoma Dioscoreae (D.japonica), mountain Bi Chinese yam (D.tokoro), Rhizoma Dioscoreae Septemlobae (D.septemloba)) extract and separate, can prepare by the saponin of chemical modification available from natural source, or synthetic by chemical method.Alternatively, the diosgenin (for example, the diosgenin that can get) that can use commerce to get from Sabinsa.For example, diosgenin of the present invention can use solvent such as water, pure and mild acetone to extract and separate at 0 to 50 ℃ from plant such as Japanese Rhizoma Dioscoreae and mountain Bi Chinese yam, and it is known for those skilled in the art.
In order to confirm the whitening effect of diosgenin of the present invention, measure the effect that it suppresses the synthetic and tyrosinase activity of melanin, this is to brighten the common screening technique of material, and with known skin whitening cosmetic material vitamin C relatively.As a result, diosgenin of the present invention shows that good inhibition melanin synthesizes and the effect of tyrosinase activity, and it is higher by about 10% than vitamin C under same concentrations.Therefore, diosgenin of the present invention can be used for skin whitening.
It will be apparent to one skilled in the art that, the diosgenin of formula 1 of the present invention comprises, in the middle of by substituent addition or its derivant of replace producing, suppress the synthetic and/or tyrosinase activity of melanin to show the derivant of skin whitening effect.
In skin whitening composition of the present invention, the content of diosgenin preferably can for based on composition total weight 0.0001 to 15wt%.If content is less than 0.0001wt%, whitening effect is inadequate, and if content greater than 15%, whitening effect increases a little, yet the time has stability problem in preparation.More preferably, diosgenin is involved with 0.0001 to 10wt% amount based on composition total weight.
According on the other hand, the present invention relates to comprise the cosmetic composition that is used for skin whitening of described compositions.
Except the diosgenin as effective ingredient, cosmetic composition can be included in normally used additive in the cosmetic formulations, for example, and conventional adjuvant such as antioxidant, stabilizing agent, solubilizing agent, vitamin, pigment and perfume and/or carrier.Cosmetic composition can also comprise the skin absorbs reinforcing agent that improves the skin whitening effect.
Cosmetic composition of the present invention can be prepared as any preparation for preparing usually in this area.Cosmetic composition can be configured to, for example, at the bottom of solution, suspension, Emulsion, paste, gel, paste, lotion, powder, soap, the cleaning agent that contains surfactant, grease, Powdered substrate, Emulsion substrate, the cerul, spraying etc., but be not limited thereto.More specifically, cosmetic composition can be prepared as preparation as gentle skin dew (softening toner), nutrition dew (a nutrient toner), nourishing cream (a nutrient cream), massage cream (a massage cream), essence, eye cream, cleansing cream, the clean clean papula of skin (a cleansing foam), clean water (acleansing water), beauty treatment Liniment (a pack), spraying and powder.
If the preparation of cosmetic composition of the present invention is paste, paste or gel, then animal oil, vegetable oil, wax, paraffin, starch, traganth, cellulose derivative, Polyethylene Glycol, siloxanes, bentonite, Silicon stone, Talcum, zinc oxide etc. can be used as carrier components.
If the preparation of cosmetic composition of the present invention is powder or spraying, then lactose, Talcum, Silicon stone, aluminium hydroxide, calcium silicates or polyamide powder can be used as carrier components, particularly, if preparation is spraying, can use propellant such as chlorofluorocarbon, propane/butane and dimethyl ether.
If the preparation of cosmetic composition of the present invention is solution or Emulsion, then solvent, solubilizing agent or emulsifying agent can be used as carrier components, and their example comprises water, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzylalcohol, benzyl benzoate, propylene glycol, 1,3 butylene glycol oil, glycerol aliphatic (acid) ester, Polyethylene Glycol or sorbitan fatty acid ester.
If the preparation of cosmetic composition of the present invention is a suspension, then liquid diluent such as water, ethanol and propylene glycol; Suspending agent such as ethoxylation isooctadecanol, polyoxyethylene sorbitol ester (polyoxyethylene sorbitol ester) and polyoxyethylene sorbitol acid anhydride ester (polyoxyethylene sorbitan ester); Microcrystalline Cellulose; Inclined to one side aluminium hydroxide (aluminum metahydroxide); Bentonite; Agar, traganth etc. can be used as carrier components.
If the preparation of cosmetic composition of the present invention is the cleaning agent that contains surfactant, then aliphatic alcohol sulfate, fatty alcohol ether sulphate, sulfosuccinic acid monoesters (sulphosuccinic acidmonoester), isethionate, imidazoline
Salt derivative, methyl tauride (methyltaurate), sarcosinate, fatty acid amide ether sulfate, alkyl amido betaine salt (alkylamidobetain), aliphatic alcohol, fatty glyceride, fatty acid diethanolamine, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester etc. can be used as carrier components.
In cosmetic composition of the present invention, the content of diosgenin can for based on the cosmetic composition gross weight 0.0001 to 15wt% and be preferably 0.0001 to 10wt%.
According on the other hand, the present invention relates to comprise the pharmaceutical composition that is used for skin whitening of described compositions.
In pharmaceutical composition of the present invention, the content of diosgenin can for based on described pharmaceutical composition gross weight 0.0001 to 15wt% and be preferably 0.0001 to 10wt%.
Pharmaceutical composition of the present invention can also be included in normally used suitable carriers, excipient and diluent in the preparation of drug combination.
According to the method for routine, pharmaceutical composition of the present invention can be formulated into any appropriate formulation, comprising: oral formulations such as powder, granule, tablet, capsule, suspending agent, Emulsion, syrup and aerosol; External preparation such as ointment and paste; Suppository and Injectable sterile solution.
Can be administered to mammal such as rat, mice, domestic animal and people through various approach according to pharmaceutical composition of the present invention, described various path such as oral and parenteral route (as, oral, rectum or vein, muscle, subcutaneous, go up injection in Intradermal and the cerebrovascular), be preferably percutaneous path and topical application more preferably in the parenteral route.
According to patient's age, sex, body weight, health status and method of application, can determine the effective dose of this compositions.For topical application, diosgenin can be preferably with once or five times 1.0 to 3.0ml daily dose was used 1 month or the longer time.
In addition, for Orally administered, according to patient's age, sex and body weight, diosgenin can 1 time or for several times 0.1 to 100mg/kg daily dose use.Dosage can be adjusted according to route of administration, severity of disease, patient's sex, body weight and age.Yet scope of the present invention is not limited to described dosage.
On the other hand, stimulate the result of test, find that diosgenin is safe as natural materials for people's skin as the accumulation in the specific embodiments of the invention.Therefore, diosgenin of the present invention does not have toxicity and side effect, thereby use is safe for a long time, particularly is applied to cosmetics and pharmaceutical composition.
The mode of invention
Hereinafter, the present invention is explained in more detail with reference to embodiment.Yet, the invention is not restricted to these embodiment.
Embodiment 1: diosgenin is to the synthetic inhibiting assessment of melanin
Mice B16 melanoma cells is used to measure diosgenin (Sigma) to the synthetic inhibitory action of melanin, and itself and vitamin C compare the synthetic inhibitory action of melanin.
Mouse black-in lymphoma (B-16 F10) cell inoculation is in 6 orifice plates that comprise the DMEM culture medium that is supplemented with 10%FBS (hyclone) (each hole 1 * 10
5Individual cell) on, and at 37 ℃ 5%CO
2Cultivate in the incubator, converge (confluency) up to reaching about 80%.Then, from cell, remove culture medium, substitute with the fresh culture of dilution, and at 37 ℃ 5%CO
2Cultivated 3 days in the incubator.The concentration of treatment of diosgenin is determined in 1uM, 10uM and the 50uM scope, and these concentration of treatment do not have showed cell toxicity.From cell, remove culture medium, and clean cell, carry out trypsin treatment then with PBS (phosphate buffered saline (PBS)).Reclaim cell, and use the hematimeter counting.Then, with 5,000 to 10,000rpm centrifuge cell 10 minutes is removed supernatant to obtain precipitation.Be deposited in 60 ℃ of dryings, and in 60 ℃ of water-baths, be suspended in the 1M sodium hydroxide solution of the 100 μ l that comprise 10%DMSO, to obtain the melanin in the cell.Using microplate to measure at 490nm absorbs to assess the melanin content of each cell.The result shows in following table 1.
Table 1
| Sample | Concentration of treatment (μ M) | Melanin synthesizes suppression ratio (%) |
| Vitamin C | 1 | 5 |
| Vitamin C | 10 | 30 |
| Vitamin C | 50 | 56 |
| Diosgenin | 1 | 12 |
| Diosgenin | 10 | 44 |
| Diosgenin | 50 | 67 |
As showing in the table 1, in identical concentration of treatment, diosgenin shows than the synthetic suppression ratio high about 7%, 14% and 11% of ascorbic melanin.
Embodiment 2: diosgenin is to the inhibiting assessment of tyrosinase activity
Mice B16 melanoma cells is used to measure diosgenin to inhibition of tyrosinase activity, and its inhibitory action and vitamin C compare inhibition of tyrosinase activity.
Mouse black-in lymphoma (B-16 F1) cell inoculation is in 6 orifice plates that comprise the DMEM culture medium that is supplemented with 10%FBS (hyclone) (each hole 1 * 10
5Individual cell) on, and at 37 ℃ 5%CO
2Cultivate in the incubator, converge (confluency) up to reaching about 80%.Then, from cell, remove culture medium, substitute with the fresh culture of dilution, and at 37 ℃ 5%CO
2Cultivated 3 days in the incubator.The concentration of treatment of diosgenin is defined in 1uM, 10uM and the 50uM scope, and these concentration of treatment do not have showed cell toxicity.From cell, remove culture medium, and clean cell, carry out trypsin treatment then with PBS (phosphate buffered saline (PBS)).Reclaim cell, and use the hematimeter counting.Then, with 5,000 to 10,000rpm centrifuge cell 10 minutes is removed supernatant to obtain precipitation.Use the lysis buffer precipitation that suspends again, and 12, centrifugal 10 minutes of 000rpm is with the collection supernatant.Using microplate to measure at 492nm absorbs to assess the tyrosinase activity of each cell.The result shows in following table 2.
Table 2
As showing in the table 2, in identical concentration of treatment, diosgenin shows tyrosinase activity suppression ratio higher by 11% than vitamin C, 12% and 11%.
Embodiment 3: the assessment of skin whitening effect in the animal
Brown Cavia porcellus (Tortoiseshell Cavia porcellus)---known its as the people, when being exposed to UV, increase chromogenesis---be used to measure the whitening effect of diosgenin.
In order to cause the chromogenesis in the brown Cavia porcellus by UV, has 3 * 3cm
2The shading aluminium foil of window is adhered to the skin of abdomen of the brown Cavia porcellus of defeathering, uses SE lamp (wavelength 290-320nm, Toshiba) irradiating ultraviolet light (total irradiation energy=1350mJ/cm thereon then
2).After the UV irradiation, aluminium foil is removed, then following the applying of sample (diosgenin and vitamin C).At the postradiation chromogenesis of observing increase in 2 or 3 days of UV, after about 2 weeks, reach maximum.From maximum, each sample is applied in.
Once a day or twice apply carry out 50 days.Sample is dissolved and be diluted in some solvent (propylene glycol: ethanol: apply the blended solvent of water=5: 3: 2) and with swab.Another zone only applies solvent in contrast.The appearance that accumulation stimulates also is examined.
Use chromascope (chromameter) (CR2002 chromascope, Minolta, Japan) to measure the degree of chromogenesis with the assessment effect.The result is shown in the following table 3.The L*A*B* colorimetric system is used to color classification, and the L* value is used to as the standard among the present invention.Use blank standard correction L* value, and a regional repeated measure more than five times.Chromogenesis distributes equably.Be determined at the skin aberration (Δ L*) between beginning application point and the terminal point application point, use these values then, assessment applies the effect of sample.The result shows in following table 3.
[mathematical equation 1]
Δ L*=is applying back 00 day L* value-in the initial L* value that applies day
Applying zone and contrast at sample applies zone acquisition Δ L* value and compares.According to the result, can assess the skin whitening effect of sample.
[table 3]
| Sample | Concentration of treatment (%) | Whitening effect (Δ L) |
| Diosgenin | 0.2 | 0.45 |
| Diosgenin | 1.0 | 0.66 |
| Vitamin C | 1.0 | 0.51 |
| Contrast | 0.38 |
As showing in the table 3, find that diosgenin demonstrates than the better skin whitening effect of vitamin C.In addition, in the accumulation irritant test, diosgenin does not cause that accumulation stimulates.Therefore, diosgenin is safe for skin as can be seen.
Embodiment 4: diosgenin is to the safety test of application on human skin
4-1. comprise the external preparation of diosgenin
Comprise diosgenin and ascorbic external preparation in order to confirm the safety of diosgenin, to have prepared, and carry out the safety test of external preparation application on human skin.
Use the composition preparation that shows in the following table 4 to comprise diosgenin and ascorbic external preparation.Group prepares the preparation for external application to skin that does not have tyrosinase inhibitor in contrast.Test group 1 and 2 is respectively to comprise diosgenin and ascorbic external preparation.
In order to prepare preparation for external application to skin, pure water, glycerol and butanediol are mixed and in 70 ℃ of dissolvings (water).All the other components except above three kinds of components and trimethanolamine (trimethanolamine) are in 70 ℃ of dissolvings (oil phase).Oil phase adds to aqueous phase, stirs with tentatively emulsifying with intimate mixing machine (Tokushu Kika company, Japan).At last, trimethanolamine is added to wherein.The foam that produces in the mixed solution is removed, and cool to room temperature is with the preparation preparation for external application to skin then.
Table 4
4-2. accumulation irritant test
The every kind of preparation for external application to skin for preparing among the embodiment 4-1 every other day is applied to the forearm of 30 normal adults, and kept 24 hours, with repeat, make each experimenter handle with 9 new pasters altogether, to confirm whether skin irritation is caused by diosgenin.
The paster test uses Finn chamber (Finn chamber) (Epitest Ltd, Finland) to carry out.External preparation dropwise is carried on the chamber with the amount of each paster 15ul.Take turns applying the every of paster, the reaction of skin uses following mathematical equation to keep the score.The result shows in following table 5.
[mathematical equation 2]
The average response degree=
The number of times (9 take turns) that [[quantity * highest score (4 point) that index of Response * degree of reaction/experimenter is total] * 100] ÷ detects
About degree of reaction, 1 be provided as ±, 2 for+, 4 be ++.When the average response degree less than 3 the time, it is safe that compositions is confirmed as skin.
[table 5]
As be displayed in Table 5, in test group 1, corresponding to ± ,+and ++ the experimenter be counted 4,0 and 0 respectively, though other people does not show reaction.In addition, the average response degree of calculating is that 0.37 ([(4 * 1)/(20 * 4)] * 100/9=0.37), it shows that less than 3 compositions of the present invention is safe for people's skin.
As showing in 5, the external preparation that comprises diosgenin (test group 1) does not cause that significant accumulation stimulates, as matched group with comprise ascorbic external preparation.Therefore, find that diosgenin according to the present invention is safe for people's skin.
[industrial applicability]
According to the present invention, diosgenin demonstrates to tyrosinase activity and the melanin synthetic inhibitory action higher than known skin whitener vitamin C. In addition, diosgenin does not have showed cell toxicity and skin complication, therefore is applied to safely cosmetics, medicine and food compositions.
Claims (5)
1. skin whitening composition, it comprises the diosgenin as active component.
2. the cosmetic composition that is used for skin whitening, it comprises the described compositions of claim 1.
3. cosmetic composition according to claim 2, wherein said compositions have and are selected from following preparation: at the bottom of solution, suspension, Emulsion, paste, gel, paste, lotion, powder, soap, grease, Powdered substrate, Emulsion substrate, the cerul and spraying.
4. be used to prevent and treat the pharmaceutical composition of melasma or freckle, it comprises the described compositions of claim 1.
5. skin whitening composition according to claim 1, wherein the content of diosgenin be based on described composition total weight 0.0001 to 15wt%.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2008/000046 WO2009088109A1 (en) | 2008-01-04 | 2008-01-04 | Composition for skin whitening containing diosgenin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101951880A true CN101951880A (en) | 2011-01-19 |
Family
ID=40853215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008801260865A Pending CN101951880A (en) | 2008-01-04 | 2008-01-04 | Composition for skin whitening containing diosgenin |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2010535758A (en) |
| CN (1) | CN101951880A (en) |
| WO (1) | WO2009088109A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107073056A (en) * | 2014-03-31 | 2017-08-18 | 株式会社爱茉莉太平洋 | Composition containing high mountain wormwood extract |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5383384B2 (en) * | 2009-08-27 | 2014-01-08 | 株式会社ノエビア | Anti-aging agent, antioxidant, whitening agent, and immunostimulant |
| JP2012020950A (en) * | 2010-07-13 | 2012-02-02 | Kao Corp | Inhibitor of endothelin action and whitening agent |
| JP5718700B2 (en) * | 2011-03-29 | 2015-05-13 | 花王株式会社 | New sesterterpene compound, antibacterial agent and topical skin preparation |
| US20150126464A1 (en) | 2013-01-21 | 2015-05-07 | Resilio Company Limited | Therapeutic drug and therapeutic method for neurological diseases including alzheimer's disease associated with 1,25d3-marrs |
| KR101632948B1 (en) * | 2014-05-13 | 2016-06-27 | (주)케어젠 | Peptides Having Activities for Anti-inflammation, Bone Formation and Stimulation Hair Growth and Uses Thereof |
| KR101713127B1 (en) * | 2014-05-13 | 2017-03-10 | (주)케어젠 | Peptides Having Activity for Increasing Melanin Synthesis and Inhibiting Fat Synthesis and Uses Thereof |
| KR101702441B1 (en) * | 2015-03-30 | 2017-02-06 | (주)셀인바이오 | Cosmetic composition for skin whitening |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5855500A (en) * | 1981-09-25 | 1983-04-01 | Tokiwa Yakuhin Kogyo Kk | Preparation of 16-dehydropregnenolone |
| JPH06219934A (en) * | 1992-11-26 | 1994-08-09 | Dowa Mining Co Ltd | Skin-whitening cosmetic |
| JPH08133950A (en) * | 1994-11-07 | 1996-05-28 | Shiseido Co Ltd | Skin preparation for external use |
| JP2001019618A (en) * | 1999-07-06 | 2001-01-23 | Shiseido Co Ltd | Bleaching agent and skin preparation for external use comprising the same formulated therein |
| FR2799645B1 (en) * | 1999-10-13 | 2004-04-30 | Oreal | USE OF DHEA OR ITS PRECURSORS OR METABOLIC DERIVATIVES AS DEPIGMENTANT |
| FR2811561B1 (en) * | 2000-07-13 | 2003-03-21 | Oreal | COMPOSITION, ESPECIALLY COSMETIC, CONTAINING DHEA AND / OR A CHEMICAL OR BIOLOGICAL PRECURSOR OR DERIVATIVE THEREOF, AND A METALLOPROTEINASE INHIBITOR |
| FR2817747B1 (en) * | 2000-12-11 | 2004-12-03 | Oreal | USE OF AT LEAST ONE SAPOGENIN, OR A NATURAL EXTRACT CONTAINING IT, TO PREVENT THE SIGNS OF SKIN AGING |
| FR2820320B1 (en) * | 2001-02-02 | 2003-04-04 | Oreal | SUSPENSION OF LIPOPHILIC ACTIVE INGREDIENT NANOSPHERES STABILIZED BY WATER-DISPERSIBLE POLYMERS |
| FR2828100B1 (en) * | 2001-08-02 | 2004-09-24 | Galderma Res & Dev | REVERSE EMULSION COMPOSITION CONTAINING DHEA AND / OR ITS PRECURSORS OR DERIVATIVES, AND ITS USE IN COSMETICS AND DERMATOLOGY |
| FR2837704B1 (en) * | 2002-04-02 | 2005-01-14 | Oreal | USE OF SAPOGENINE, OR NATURAL EXTRACT CONTAINING THEM, FOR THE TREATMENT OF OLIGOSEBORRHEIC DRY SKINS |
| JP2004352658A (en) * | 2003-05-29 | 2004-12-16 | Shiseido Co Ltd | External preparation for skin |
| JP2007274985A (en) * | 2006-04-07 | 2007-10-25 | Takara Bio Inc | Food containing treated product derived from dioscorea esculenta |
| KR100795514B1 (en) * | 2006-07-06 | 2008-01-16 | 바이오스펙트럼 주식회사 | Skin whitening composition containing diosgenin |
| KR100782600B1 (en) * | 2006-09-12 | 2007-12-06 | 바이오스펙트럼 주식회사 | Skin anti-aging composition comprising diosgenin and diosin |
-
2008
- 2008-01-04 JP JP2010519847A patent/JP2010535758A/en active Pending
- 2008-01-04 WO PCT/KR2008/000046 patent/WO2009088109A1/en active Application Filing
- 2008-01-04 CN CN2008801260865A patent/CN101951880A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107073056A (en) * | 2014-03-31 | 2017-08-18 | 株式会社爱茉莉太平洋 | Composition containing high mountain wormwood extract |
| CN107073056B (en) * | 2014-03-31 | 2021-04-02 | 株式会社爱茉莉太平洋 | Composition containing Alpine wormwood extract |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010535758A (en) | 2010-11-25 |
| WO2009088109A1 (en) | 2009-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100923141B1 (en) | Skin whitening composition comprising arbutin beta derivative | |
| JP5675112B2 (en) | Cosmetic composition for skin whitening containing arctin, arctigenin or a mixture thereof as an active ingredient | |
| CN101951880A (en) | Composition for skin whitening containing diosgenin | |
| CN102821742A (en) | Inhibitor for melanin, and cosmetic composition containing same | |
| EP2170255B1 (en) | Use of lignan compound for anti-wrinkle treatment | |
| JP2011246353A (en) | Skin external preparation | |
| WO2016110276A1 (en) | Topical composition containing obakunone and skin-whitening method using same | |
| JP2010100554A (en) | Melanin formation inhibitor | |
| KR102154927B1 (en) | A cosmetic composition for anti-aging, anti-oxidant, skin regeneration comprising chlorogenic acid, ferulic acid, resveratrol, and Streptococcus thermophilus fermented extract | |
| KR100795514B1 (en) | Skin whitening composition containing diosgenin | |
| CN103796631A (en) | Compositions for whitening skin comprising madecassoside | |
| JP5000964B2 (en) | Testosterone 5α-reductase activity inhibitor, androgen receptor antagonist, use thereof, and method for suppressing androgen activity expression | |
| US9730872B2 (en) | Method for improving skin conditions with veratric acid or acceptable salt thereof as an active ingredient | |
| KR101430636B1 (en) | Functional cosmetic composition comprising ginsenosides Rh2 and Rg3 | |
| CN101854909B (en) | Skin-whitening agent containing platycodin D | |
| US8217074B2 (en) | Use of sargachromenol | |
| EP2561883A2 (en) | Novel vascular endothelial growth factor expression inhibitors | |
| JP5155543B2 (en) | Endothelin-1 production inhibitor, hexosaminidase release inhibitor, anti-inflammatory / whitening skin preparation, endothelin-1 production inhibition method, and hexosaminidase release inhibition method | |
| US20100061948A1 (en) | Composition for skin whitening comprising artemisinine | |
| KR101179308B1 (en) | Composition for skin-whitener containing saponified evening primrose seed oil as an effective ingredient | |
| JP5405782B2 (en) | Ceramide production promoter and moisturizer | |
| JP5167042B2 (en) | Ceramide production promoter, moisturizer and external preparation for skin | |
| KR20040059004A (en) | Skin Whitening Cosmetic containing a herb extract with inhibitory activity of melanin formation | |
| JP2002363085A (en) | Antiandrogenic hormone preparation, hair growing cosmetic, inhibitor for sebum secretion and inhibitor for prostatic hypertrophy | |
| JP6433678B2 (en) | External preparations and internal preparations containing the extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20110119 |